SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-015079
Filing Date
2020-06-16
Accepted
2020-06-16 10:53:25
Documents
5
Period of Report
2020-06-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea123091-8k_immucellcorp.htm 8-K 35603
2 PRESS RELEASE OF THE COMPANY DATED JUNE 16, 2020 ea123091ex99-1_immucell.htm EX-99.1 20084
3 NOTE PURCHASE AGREEMENT EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF THE MAINE T ea123091ex99-2_immucell.htm EX-99.2 98759
4 SUBORDINATED PROMISSORY NOTE FOR $500,000 EXECUTED BY IMMUCELL CORPORATION IN FA ea123091ex99-3_immucell.htm EX-99.3 62699
5 GRAPHIC ex99-1_001.jpg GRAPHIC 4121
  Complete submission text file 0001213900-20-015079.txt   224181
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 20965388
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences